📊 GNLX Key Takeaways
Is GENELUX Corp (GNLX) a Good Investment?
GENELUX is a pre-revenue/development-stage pharmaceutical company with near-zero revenue ($8K), unsustainable operating losses ($9.2M), and negative free cash flow ($7.0M), indicating runway of approximately 1.5 years at current burn rates. While the company maintains adequate liquidity ($9.3M cash, 3.68x current ratio), the complete absence of commercial revenue, deteriorating cash position, and escalating net losses represent extreme fundamental weakness.
Genelux is effectively pre-revenue ($8k) with extremely negative margins and large operating losses (operating income -$33.21M, net income -$32.15M). While near-term liquidity appears adequate (current ratio 2.43x) and equity is positive, cash of $5.33M is insufficient versus a -$25.27M operating cash burn and $9.06M in long-term debt, indicating likely near-term financing needs. Until revenue traction or a material reduction in operating losses is demonstrated, fundamentals remain weak.
GENELUX Corp Key Strengths (GNLX)
- Adequate short-term liquidity with $9.3M cash reserves and 3.68x current ratio
- Moderate leverage with 0.40x debt-to-equity ratio reducing financial stress
- Positive insider activity with 5 Form 4 filings in 90 days
- Current ratio of 2.43x provides near-term liquidity
- Positive shareholders’ equity ($11.54M)
- Low capital intensity (capex $1.10M)
GNLX Stock Risks: GENELUX Corp Investment Risks
- Near-zero revenue ($8K) indicates no commercial product sales or severe revenue collapse
- Operating cash burn of $6.1M annually with only 1.5 years of cash runway remaining
- Unsustainable operating losses of $9.2M with negative net margin of -111,600%
- No visible path to profitability; company dependent on clinical development success
- Sustained heavy losses and cash burn (OCF -$25.27M)
- Minimal revenue base ($8k) offers no path to scale
- Leverage without coverage (no interest coverage; $9.06M long-term debt)
Key Metrics to Watch
- Cash and equivalents decline rate relative to operating burn
- Revenue generation timing and magnitude from any approved programs
- Operating expense reduction or maintenance of current burn rate
- Operating cash flow (burn rate)
- Cash and equivalents (runway)
GENELUX Corp (GNLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.68x current ratio provides a solid financial cushion.
GNLX Profit Margin, ROE & Profitability Analysis
GNLX vs Healthcare Sector: How GENELUX Corp Compares
How GENELUX Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GENELUX Corp Stock Overvalued? GNLX Valuation Analysis 2026
Based on fundamental analysis, GENELUX Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GENELUX Corp Balance Sheet: GNLX Debt, Cash & Liquidity
GNLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GENELUX Corp's revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.95 indicates the company is currently unprofitable.
GNLX Revenue Growth, EPS Growth & YoY Performance
GNLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.0K | -$6.5M | $-0.19 |
| Q2 2025 | $8.0K | -$6.6M | $-0.20 |
| Q1 2025 | $8.0K | -$7.5M | $-0.21 |
| Q3 2024 | $8.0K | -$5.3M | $-0.19 |
| Q2 2024 | $8.0K | -$5.8M | $-0.22 |
| Q1 2024 | $8.0K | -$7.9M | $-0.29 |
| Q3 2023 | $170.0K | -$1.7M | $-0.19 |
| Q2 2023 | $170.0K | -$2.8M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GENELUX Corp Dividends, Buybacks & Capital Allocation
GNLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GENELUX Corp (CIK: 0001231457)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GNLX
What is the AI rating for GNLX?
GENELUX Corp (GNLX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GNLX's key strengths?
Claude: Adequate short-term liquidity with $9.3M cash reserves and 3.68x current ratio. Moderate leverage with 0.40x debt-to-equity ratio reducing financial stress. ChatGPT: Current ratio of 2.43x provides near-term liquidity. Positive shareholders’ equity ($11.54M).
What are the risks of investing in GNLX?
Claude: Near-zero revenue ($8K) indicates no commercial product sales or severe revenue collapse. Operating cash burn of $6.1M annually with only 1.5 years of cash runway remaining. ChatGPT: Sustained heavy losses and cash burn (OCF -$25.27M). Minimal revenue base ($8k) offers no path to scale.
What is GNLX's revenue and growth?
GENELUX Corp reported revenue of $8.0K.
Does GNLX pay dividends?
GENELUX Corp does not currently pay dividends.
Where can I find GNLX SEC filings?
Official SEC filings for GENELUX Corp (CIK: 0001231457) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GNLX's EPS?
GENELUX Corp has a diluted EPS of $-0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GNLX's fundamental grade?
Based on our AI fundamental analysis in May 2026, GENELUX Corp has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GNLX stock overvalued or undervalued?
Valuation metrics for GNLX: ROE of -39.0% (sector avg: 15%), net margin of -111,600.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GNLX's AI grade for 2026?
Our dual AI analysis gives GENELUX Corp a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GNLX's free cash flow?
GENELUX Corp's operating cash flow is $-6.1M, with capital expenditures of $921.0K. FCF margin is -87,250.0%.
How does GNLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -111,600.0% (avg: 12%), ROE -39.0% (avg: 15%), current ratio 3.68 (avg: 2).